Brookside Capital
VC Fund
San Francisco, United States
Brookside Capital is a VC fund in San Francisco focused on Biotechnology and Health Care. They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 22%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Brookside Capital invests in
BiotechnologyHealth CareTherapeuticsMedicalGenetics
Stages Brookside Capital invests in
Series CSeries BSeries DSeries EFunding Round
Countries Brookside Capital invests in
United StatesChinaIndonesiaSingaporeSouth Korea
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Investment Focus
Industry
- Biotechnology 15 (33%)
- Health Care 12 (27%)
- Therapeutics 7 (16%)
- Medical 6 (13%)
- Genetics 6 (13%)
Stage
- Series C 10 (22%)
- Series B 7 (16%)
- Series D 7 (16%)
- Series E 4 (9%)
- Funding Round 3 (7%)
Country
- United States 28 (62%)
- China 2 (4%)
- Indonesia 1 (2%)
- Singapore 1 (2%)
- South Korea 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Krizek
Director
|
Director | Total investments: 1 | Find email | |
|
Thomas L. Rea
Board of Advisors
|
Board of Advisors | Total investments: 0 | Find email | |
Craig Law
Operations Manager
|
Operations Manager | Total investments: 0 | Find email | |
Doreen Marino
Director of Client Services
|
Director of Client Services | Total investments: 0 | Find email | |
James Rea
President
|
President | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Anaplan
|
Anaplan is driving a new age of connected planning. Large and fast-growing organizations use Anaplan’s cloud platform in every business function to make better-informed plans and decisions and drive faster, more effective planning processes. Anaplan also provides support, training, and planning transformation advisory services. Anaplan is aprivately held company based in San Francisco with 16 offices and over 150 expert partners worldwide. To learn more, visit anaplan.com. | $90M / Series E / Jan 16, 2016 | |
Socar
|
Socar is a Korean eco-friendly car sharing community that allows travelers to share cars with others who are traveling the same route.Socar has raised an $18 million round of funding in 2015 which was one of the highest funding deals for a South Korean startup to date. Most notably, it was led by a US investor: Bain Capital, a private investmentfirm with $80 billion in assets under management.Socar was founded in March 2012, and it has a website and smartphone apps that let users book cars for their own use. Service has over 1,700,000 registered users, 50,000 of whom use the service each month. Around 80,000 transactions per month — that’s more than one car booking each 30 seconds. | $48.3M / Series B / Nov 27, 2015 | |
SevOne
|
SevOne provides the only digital infrastructure performance monitoring solution engineered for Speed at Scale for the world’s most demanding service-delivery environments. The patented SevOne ClusterTM architecture leverages distributed computing to monitor any device in the service-delivery path, integrating performance metrics, flows, and logs atscale, while providing answers in seconds to prevent performance-impacting outages. SevOne’s global customer base includes 5 of the 7 top global investment services companies, enterprises, CSPs, MSPs and MSOs. SevOne serves organizations that are looking to complex, dynamic next-generation infrastructure such as software=defined networks, orchestrated containers, and cloud technologies to support their business goals. The company is backed by Bain Capital Ventures and was named a Visionary in Gartner’s 2015 Magic Quadrant for Network Performance Monitoring and Diagnostics. | $47.1M / Series C / Sep 23, 2015 | |
Translate Bio
|
Translate Bio is a biotechnology company that in biotechnology, RNA therapeutics, and rare diseases. Translate Bio is a therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. | $63.8M / Series B / Jul 23, 2015 | |
Giosis
|
Giosis, the company behind Qoo10, operates an e-marketplace offering sellers customisable sales strategies and buyers an extensive product portfolio. It is a joint venture established between eBay Inc. and Gmarket Inc. founder, Mr Ku Young Bae, in April 2010. Today, Giosis provides seven localised marketplaces, Qoo10, in five countries – China,Hong Kong, Japan, Indonesia, Malaysia and Singapore. It partners esteemed enterprises such as Mecox Lane and Yahoo to enable e-commerce of the best deals in almost every country. Qoo10’s five markets transacted SGD278 million in 2012, almost doubling 2011's SGD150 million. In Singapore, its daily transactions are about 30,000, translating into monthly sales volume of SDG15 million and annual sales volume of SGD90 million in 2012. As of January 2013, 960,000 Qoo10 mobile apps have been downloaded across the five Qoo10 e-marketplaces. Singapore contributed some 580,000 downloads. About 20 per cent of the overall sales come from mobile sales, and this number is expected to rise to 30 per cent within 2013.As of March 2013, there are about 50,000 registered sellers on Qoo10 Singapore. About 150 sellers transact at least SGD10,000 every month. There are about 900,000 registered users on Qoo10 Singapore. More than 1,000 new users are registered on Qoo10 Singapore every day since January 2012. | $82.1M / Series A / Jul 23, 2015 | |
Qoo10-Indonesia
|
PT.Giosis(Qoo10) is founded as a joint venture with eBay; the world’s largest ecommerce service provider, to build a dynamic Pan Asia emarketplace.Giosis Gmarket offers an innovative ecommerce platform providing the customers fun, convenient, price competitive and secure shopping experiences for reliable goods and services from all over theworld.Kalau ada pertanyaan, kamu bisa menghubugi customer service kami di 021-2934-3525 (senin s/d jumat 08.00 s/d 17.00) atau kirim e-mail ke help@qoo10.co.id | $82M / Series A / Jul 20, 2015 | |
REGENXBIO
|
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologicdisorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia. | $70.5M / Series D / May 20, 2015 | |
MuleSoft
|
MuleSoft makes it easy to connect the world’s applications, data, and devices. They provide a software platform that enables organizations to easily build application networks using APIs. APIs are the digital glue that allows applications to talk to each other and exchange data. Their flexible, unified platform connects nearly any application orsystem by leveraging APIs to quickly and securely share data, regardless of format or source, in application networks.It was founded in 2006 and is headquartered in San Francisco, California,. | $128M / Series G / May 19, 2015 | |
Docusign
|
DocuSign operates a cloud-based electronic signature platform that helps small- and medium-sized businesses, enterprises, and individuals collect information, automate data workflows, and sign on various devices.The company’s platform automates manual and paper-based processes that allow users to manage various aspects of documented businesstransactions, including identity management, authentication, digital signature, forms and data collection, collaboration, and workflow automation and storage.The company also provides training and support services. Its platform serves the sales, human resources, finance, information technology, operations, legal, marketing, facilities, support, product management, and procurement departments in the financial services, healthcare, technology, higher education, insurance, real estate, life sciences, and government sectors in the United States and internationally.DocuSign was incorporated in 2003 and is based in San Francisco, California with additional offices in London, Sydney, Sao Paulo, and Dublin. | $300M / Series F / May 12, 2015 | |
Voyager Therapeutics
|
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well asprocess development and production.The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. | Series B / Apr 13, 2015 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Brookside Capital invest in?
Brookside Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brookside Capital?
Public channels for Brookside Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Brookside Capital?
The team at Brookside Capital includes Daniel Krizek (Director), Thomas L. Rea (Board of Advisors) and Craig Law (Operations Manager), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
